To address these hypotheses, we first profiled two independent DLBCL cohorts with T-GEP, FISH, and IHC, in order to define COO subtyping, MYC, and BCL-2 status and expression levels of biomarkers of DDR activation and oxidative DNA damage (γH2AX and 8-OHdG). The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.